Pendragon upgrades full-year underlying PBT expectation

Pendragon PLC (LON:PDG) has provided a trading update and increases underlying profit before tax guidance for the full year to 31 December 2021 from approximately £70.0m to approximately £80.0m.

The Group has continued to perform strongly during the first two months of Q4 FY21.  Whilst the shortfall in the supply of new vehicles persists, customer demand and order levels have continued at a higher level than last year.  Despite demand outpacing deliveries,  the shortfall in October and November was lower than we had previously anticipated and performance has been supported by a strong gross profit per unit.

In addition, we are continuing to see robust performance in used vehicles following successful implementation of the Group’s strategy, which continues to drive improved gross profit per unit, underpinned by favourable market conditions.  The overall Group performance continues to be supported by cost and efficiency savings realised through the successful delivery of the strategy.

We remain cautious about potential further disruption from Covid-19 to both our local markets and global supply chains, however, our strong financial performance, with only one month of the financial year remaining, means we now expect Group underlying profit before tax for FY21 to be approximately £80.0m. The Board is confident that the Pendragon’s strategy positions it well to respond to the ongoing market uncertainty and to capitalise on any resultant opportunities.

Click to view all articles for the EPIC: ,
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Pendragon plc

    More articles like this

    Guild Esports sign two-year gaming chair sponsorship with Razer

    Guild Esports plc (LON:GILD; OTCQB: GULDF), a global teams organisation and lifestyle brand, has welcome Razer as the Company’s Official Gaming Chair Partner with the signing of a two-year global sponsorship deal. The total contract value, which

    Redde Northgate trading ahead of expectations

    Redde Northgate plc (LON:REDD), the leading integrated mobility solutions platform providing services across the vehicle lifecycle, has announced a trading update for the year ended 30 April 2022, ahead of its results for the year scheduled

    Inchcape

    Inchcape update on Russian operations

    Inchcape plc (LON:INCH) is deeply saddened by the ongoing conflict in Ukraine and the enormous humanitarian impact on all those affected. We share the hopes of the world for a peaceful resolution. In light of the current

    STRIX GROUP PLC ORD 1P

    Strix Group to conduct investor presentation on 31st March 2022

    Strix Group plc (LON:KETL), the global leader in the design, manufacture and supply of kettle safety controls and other complementary water temperature management components will be conducting an investor presentation covering their Full Year results to the period

    City of London Investment Group plc

    City of London Investment Group Barry Olliff increases holding

    City of London Investment Group plc (LON:CLIG), a leading specialist asset management group offering a range of institutional and retail products investing primarily in closed-end funds, stated that it has been notified that Stable View III LP,

    CentralNic

    CentralNic Group continue to beat expectations (Analyst Interview)

    CentralNic Group Plc (LON:CNIC) is the topic of conversation when Bob Liao Director and Research Analyst at Zeus Capital joins DirectorsTalk Interviews. Bob provides us with an overview of VGL, explains how the acquisition fits in with CentalNic’s business,

    Guild Esports wins fifth major trophy

    Guild Esports plc (LON:GILD; OTCQB: GULDF), a global team organisation and lifestyle brand, has announced that it has won its fifth major trophy after its Fortnite pro-player, Henrik Mclean (‘Hen’), achieved first place in the prestigious Fortnite

    Oncimmune signs new commercial follow-on contract 

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a new commercial follow-on contract with a world-leading medical research organisation based in the US, to validate the findings from a previous